ETH’s Paul Scherrer Institute has launched Araris Biotech to deliver production technology for site-specific ADCs that enable them to be used without being engineered from each patient.

Paul Scherrer Institute, part of the Domain of the Swiss Federal Institutes of Technology (ETH Domain) system, has unveiled Switzerland-based biotech company Araris Biotech to commercialise enhanced antibody-drug conjugates (ADCs). Founded in January 2019, Araris Biotech is working on a technology for producing site-specific ADCs, antibodies chained to a biologically-active cytotoxic compound to treat diseases…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.